CYP4F11

From Wikipedia, the free encyclopedia
Jump to: navigation, search
CYP4F11
Identifiers
Aliases CYP4F11, CYPIVF11, cytochrome P450 family 4 subfamily F member 11
External IDs MGI: 3645508 HomoloGene: 117991 GeneCards: 57834
Orthologs
Species Human Mouse
Entrez
Ensembl
UniProt
RefSeq (mRNA)

NM_001128932
NM_021187

NM_001101588

RefSeq (protein)

NP_001122404.1
NP_067010.3

n/a

Location (UCSC) Chr 19: 15.91 – 15.93 Mb Chr 17: 32.66 – 32.68 Mb
PubMed search [1] [2]
Wikidata
View/Edit Human View/Edit Mouse

CYP4F11 (cytochrome P450, family 4, subfamily F, polypeptide 11) is a protein that in humans is encoded by the CYP4F11 gene.[1] This gene encodes a member of the cytochrome P450 superfamily of enzymes. The cytochrome P450 proteins are monooxygenases which catalyze many reactions involved in drug metabolism and synthesis of cholesterol, steroids and other lipids. This gene is part of a cluster of cytochrome P450 genes on chromosome 19. Another member of this family, CYP4F2, is approximately 16 kb away. Alternatively spliced transcript variants encoding the same protein have been found for this gene.[2]

Expression[edit]

CYP4F11 is expressed in liver, kidney, heart, brain, and skeletal muscle and is overexpressed in ovarian and colon cancers; perhaps relativant to its overexpression in ovarian cancer, its gene has an estrogen receptor α responsive site in its Promoter (genetics) site.[3]

Activities and possible functions[edit]

CYP4F11 is active in metabolism of many drugs including benzphetamine, ethylmorphine, chlorpromazine, imipramine, and erythromycin;.[3]

The cytochrome is also able to hydroxylate short-chain and 3-hydroxylated medium chain fatty acidss by attaching a hydroxyl residue to their terminal carbon by omega oxidation in a reaction that may be critical to the processing of these fatty acids.[4] It likewise omega-hydroxylates Vitamin Ks including menaquinone in a metabolic step which is essential for their further metabolism by beta oxidation and probably thereby their removal by catabolism to regulate their tissue levels.[4]

CYP4F11 omega-hydroxylates leukotriene B4 (LTB4) to 20-hydroxy-LTB4, 5-Hydroxyicosatetraenoic acid (5-HETE) to 20-hydroxy-5-HETE (i.e. 5,20-diHETE), 12-hydroxyeicosatetraenoic acid (12-HETE) to 12,20-diHETE, lipoxins and possibly 5-oxo-eicosatetraenoic acid (5-oxo-ETE) to their 20-hydroxy metabolites; these reactions begin the inactivation of these pro- (LTB4, 5-HETE, 12-HETE, and 5-oxo-ETE) and anti- (lipoxins) cell signaling agents; however, it is relatively weak compared to, and therefore possibly not as physiologically relevant as, other CYP4Fs such as CYP4F2, CYP4F3a, CYP4F3b, CYP4A11 and CYP4F2 in doing so.[3][4] The enzyme also hydroxylates arachidonic acid (i.e. eicosatetraenoic acid to 20-hydroxeicosatetraenoic acid) (20-HETE) although other cytochromes such as CYP4A11 and CYP4F2 appear more important in this metabolic conversion.[3] 20-HETE is a short-lived potent signaling agent that functions to regulate blood flow, vascularization, blood pressure, and kidney tubule absorption of ions in rodents and possibly humans.[5] Gene polymorphism variants of CYP4A11 are associated with the development of hypertension and cerebral infarction (i.e. ischemic stroke) in humans (see 20-Hydroxyeicosatetraenoic acid).[6][7][8][9][10][11] In spite of its relative impotency and/or importance in accomplishing these omega-hydroxylations, CYP4F11 may contribute to them in certain tissues.

Further reading[edit]

Johnson AL, Edson KZ, Totah RA, Rettie AE. Cytochrome P450 ω-Hydroxylases in Inflammation and Cancer. Adv. Pharmacol. 74:223-62, 2015.[4]

References[edit]

  1. ^ Cui X, Nelson DR, Strobel HW (September 2000). "A novel human cytochrome P450 4F isoform (CYP4F11): cDNA cloning, expression, and genomic structural characterization". Genomics 68 (2): 161–6. doi:10.1006/geno.2000.6276. PMID 10964514. 
  2. ^ "Entrez Gene: CYP4F11". 
  3. ^ a b c d Hardwick JP (June 2008). "Cytochrome P450 omega hydroxylase (CYP4) function in fatty acid metabolism and metabolic diseases". Biochemical Pharmacology 75 (12): 2263–75. doi:10.1016/j.bcp.2008.03.004. PMID 18433732. 
  4. ^ a b c d Johnson AL, Edson KZ, Totah RA, Rettie AE (2015). "Cytochrome P450 ω-Hydroxylases in Inflammation and Cancer". Advances in Pharmacology 74: 223–62. doi:10.1016/bs.apha.2015.05.002. PMID 26233909. 
  5. ^ Hoopes SL, Garcia V, Edin ML, Schwartzman ML, Zeldin DC (July 2015). "Vascular actions of 20-HETE". Prostaglandins & Other Lipid Mediators 120: 9–16. doi:10.1016/j.prostaglandins.2015.03.002. PMID 25813407. 
  6. ^ Gainer JV, Bellamine A, Dawson EP, Womble KE, Grant SW, Wang Y, Cupples LA, Guo CY, Demissie S, O'Donnell CJ, Brown NJ, Waterman MR, Capdevila JH (January 2005). "Functional variant of CYP4A11 20-hydroxyeicosatetraenoic acid synthase is associated with essential hypertension". Circulation 111 (1): 63–9. doi:10.1161/01.CIR.0000151309.82473.59. PMID 15611369. 
  7. ^ Gainer JV, Lipkowitz MS, Yu C, Waterman MR, Dawson EP, Capdevila JH, Brown NJ (August 2008). "Association of a CYP4A11 variant and blood pressure in black men". Journal of the American Society of Nephrology 19 (8): 1606–12. doi:10.1681/ASN.2008010063. PMID 18385420. 
  8. ^ Fu Z, Nakayama T, Sato N, Izumi Y, Kasamaki Y, Shindo A, Ohta M, Soma M, Aoi N, Sato M, Ozawa Y, Ma Y (March 2008). "A haplotype of the CYP4A11 gene associated with essential hypertension in Japanese men". Journal of Hypertension 26 (3): 453–61. doi:10.1097/HJH.0b013e3282f2f10c. PMID 18300855. 
  9. ^ Mayer B, Lieb W, Götz A, König IR, Aherrahrou Z, Thiemig A, Holmer S, Hengstenberg C, Doering A, Loewel H, Hense HW, Schunkert H, Erdmann J (October 2005). "Association of the T8590C polymorphism of CYP4A11 with hypertension in the MONICA Augsburg echocardiographic substudy". Hypertension 46 (4): 766–71. doi:10.1161/01.HYP.0000182658.04299.15. PMID 16144986. 
  10. ^ Sugimoto K, Akasaka H, Katsuya T, Node K, Fujisawa T, Shimaoka I, Yasuda O, Ohishi M, Ogihara T, Shimamoto K, Rakugi H (December 2008). "A polymorphism regulates CYP4A11 transcriptional activity and is associated with hypertension in a Japanese population". Hypertension 52 (6): 1142–8. doi:10.1161/HYPERTENSIONAHA.108.114082. PMID 18936345. 
  11. ^ Ding H, Cui G, Zhang L, Xu Y, Bao X, Tu Y, Wu B, Wang Q, Hui R, Wang W, Dackor RT, Kissling GE, Zeldin DC, Wang DW (March 2010). "Association of common variants of CYP4A11 and CYP4F2 with stroke in the Han Chinese population". Pharmacogenetics and Genomics 20 (3): 187–94. doi:10.1097/FPC.0b013e328336eefe. PMID 20130494. 

Further reading[edit]

  • Dhar M, Sepkovic DW, Hirani V, Magnusson RP, Lasker JM (March 2008). "Omega oxidation of 3-hydroxy fatty acids by the human CYP4F gene subfamily enzyme CYP4F11". Journal of Lipid Research 49 (3): 612–24. doi:10.1194/jlr.M700450-JLR200. PMID 18065749. 
  • Bonaldo MF, Lennon G, Soares MB (September 1996). "Normalization and subtraction: two approaches to facilitate gene discovery". Genome Research 6 (9): 791–806. doi:10.1101/gr.6.9.791. PMID 8889548. 
  • Nelson DR, Zeldin DC, Hoffman SM, Maltais LJ, Wain HM, Nebert DW (January 2004). "Comparison of cytochrome P450 (CYP) genes from the mouse and human genomes, including nomenclature recommendations for genes, pseudogenes and alternative-splice variants". Pharmacogenetics 14 (1): 1–18. doi:10.1097/00008571-200401000-00001. PMID 15128046. 
  • Simpson AE (March 1997). "The cytochrome P450 4 (CYP4) family". General Pharmacology 28 (3): 351–9. doi:10.1016/S0306-3623(96)00246-7. PMID 9068972. 

This article incorporates text from the United States National Library of Medicine, which is in the public domain.